Scarica l'app Stockscreener
7.82
0.38%
-0.03
Dopo l'orario di chiusura:
7.82
Precedente Chiudi:
$7.85
Aprire:
$7.83
Volume 24 ore:
37,755
Relative Volume:
0.51
Capitalizzazione di mercato:
$753.33M
Reddito:
$106.66M
Utile/perdita netta:
$15.16M
Rapporto P/E:
83.64
EPS:
0.0935
Flusso di cassa netto:
$6.37M
1 W Prestazione:
+4.13%
1M Prestazione:
+1.56%
6M Prestazione:
+3.44%
1 anno Prestazione:
-32.70%
Intervallo 1D:
$7.60
$7.91
Intervallo di 1 settimana:
$7.575
$8.15
Portata 52W:
$6.11
$13.75
Gyre Therapeutics Inc Stock (GYRE) Company Profile
Nome
Gyre Therapeutics Inc
Settore
Industria
Telefono
(858) 567-7770
Indirizzo
12770 HIGH BLUFF DRIVE, SAN DIEGO
Compare GYRE vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GYRE
Gyre Therapeutics Inc
|
7.82 | 756.22M | 106.66M | 15.16M | 6.37M | 0.0935 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-10 | Iniziato | Jefferies | Buy |
| 2025-08-26 | Iniziato | H.C. Wainwright | Buy |
| 2025-03-11 | Iniziato | Noble Capital Markets | Outperform |
| 2021-04-29 | Ripresa | Stephens | Overweight |
| 2021-02-10 | Iniziato | Piper Sandler | Overweight |
| 2020-05-21 | Iniziato | Raymond James | Outperform |
| 2019-01-04 | Iniziato | Oppenheimer | Outperform |
| 2018-02-12 | Reiterato | B. Riley FBR, Inc. | Buy |
| 2018-02-09 | Reiterato | Chardan Capital Markets | Buy |
| 2017-12-08 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-06-12 | Iniziato | Chardan Capital Markets | Buy |
| 2017-06-06 | Iniziato | Ladenburg Thalmann | Buy |
| 2016-06-30 | Iniziato | Rodman & Renshaw | Buy |
Mostra tutto
Gyre Therapeutics Inc Borsa (GYRE) Ultime notizie
High Growth Tech Stocks in US for February 2026 - simplywall.st
Will Gyre Therapeutics Inc outperform tech stocks2025 Price Action Summary & Real-Time Buy Zone Alerts - baoquankhu1.vn
Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) Last Week's 8.5% Decline Must Have Disappointed Public Companies Who Have a Significant Stake - 富途牛牛
Returns Recap: Is TENPREs ROIC above industry averageWeekly Investment Report & Expert Curated Trade Setups - baoquankhu1.vn
Gyre Therapeutics slumps 16%, prices $20M stock offering - MSN
Analyzing Gyre Therapeutics (NASDAQ:GYRE) and ImmunityBio (NASDAQ:IBRX) - Defense World
Gyre Therapeutics, Inc. (GYRE) Investor Outlook: Eyeing a 119% Upside with a Strong Buy Consensus - DirectorsTalk Interviews
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Receives Average Recommendation of “Hold” from Brokerages - Defense World
Can Gyre Therapeutics Inc. maintain its current growth rate2025 Retail Activity & Fast Gaining Stock Strategy Reports - mfd.ru
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Up 2.4%Still a Buy? - MarketBeat
Big Money Moves: Is MicroSectors Travel 3X Leveraged ETNs due May 29 2042 showing insider buyingWeekly Trading Summary & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
Aug Big Picture: Is Gyre Therapeutics Inc a turnaround storyJuly 2025 Spike Watch & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Trade Recap: Can Palantir Technologies Inc navigate macro headwindsMarket Risk Report & Long Hold Capital Preservation Plans - baoquankhu1.vn
Gyre Therapeutics, Inc. (GYRE) Investor Outlook: A Potential 123% Upside in the Biotech Space - DirectorsTalk Interviews
US Stocks Recap: Can Gyre Therapeutics Inc expand into new marketsWeekly Trade Analysis & Community Driven Trade Alerts - baoquankhu1.vn
Portfolio Recap: Is BCGWW a good ESG investment2025 Market Overview & Community Verified Swing Trade Signals - baoquankhu1.vn
Quarterly Risk: Does Evolus Inc have high return on assetsJuly 2025 WrapUp & High Accuracy Swing Trade Signals - baoquankhu1.vn
Tech Rally: Is TRTNPRC stock a value trapWeekly Risk Report & Stock Portfolio Risk Management - baoquankhu1.vn
Market Pulse: Will Gyre Therapeutics Inc outperform tech stocksJuly 2025 Summary & Expert-Curated Trade Recommendations - baoquankhu1.vn
Ideas Watch: What are analysts price targets for Gyre Therapeutics IncIPO Watch & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Gains Report: How Gyre Therapeutics Inc stock valuations compare to rivalsJuly 2025 Sentiment & Weekly Stock Breakout Alerts - Bộ Nội Vụ
High Growth Tech Stocks To Watch In The US Market January 2026 - simplywall.st
How Gyre Therapeutics Inc. stock compares to growth peersTrade Risk Assessment & Safe Entry Point Alerts - Улправда
Aug Big Picture: Will Gyre Therapeutics Inc stock benefit from commodity pricesJuly 2025 Closing Moves & Reliable Intraday Trade Alerts - Bộ Nội Vụ
Will Dynagas LNG Partners LP stock deliver consistent dividends2025 Breakouts & Breakdowns & Verified Short-Term Plans - Улправда
What margin trends mean for Mach Natural Resources LP stockSwing Trade & Capital Efficiency Focused Ideas - Улправда
Gyre Therapeutics (NASDAQ:GYRE) Trading Down 4.7%Time to Sell? - MarketBeat
Gyre Therapeutics, Inc. Announces Completion of the Pre-NDA Meeting on the Regulatory Strategy for F351 - marketscreener.com
GNI Group’s F351 Secures Path Toward Conditional Approval and Priority Review in China - TipRanks
Gyre Therapeutics (NASDAQ:GYRE) Shares Gap UpShould You Buy? - MarketBeat
Gyre Therapeutics stock soars after positive pre-NDA meeting in China - Investing.com Nigeria
Gyre Therapeutics stock soars after positive pre-NDA meeting in China By Investing.com - Investing.com South Africa
Altimmune, GH Research, Gyre Therapeutics And Other Big Stocks Moving Higher On Monday - Benzinga
Gyre Pharmaceuticals advances liver fibrosis drug toward China approval By Investing.com - Investing.com Canada
Gyre Therapeutics Announces Pre-NDA Meeting Success for Hydronidone - TradingView — Track All Markets
Gyre Therapeutics Announces Alignment with China’s CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting - manilatimes.net
Experimental liver fibrosis drug in China moves closer to patient use - Stock Titan
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Given Average Rating of "Hold" by Analysts - MarketBeat
Info Edge (India) Limited Stock Approaches Key Moving AverageLong-Term Growth Stocks & High Profit Market Ideas - bollywoodhelpline.com
Gyre Therapeutics president sells $45,380 in stock - MSN
Industries Limited (511034) Hits 52 Week HighSwing Trading Ideas & Build Diversified Portfolios With Ease - bollywoodhelpline.com
Undiscovered Gems in the US Market to Explore This December 2025 - Yahoo Finance
Published on: 2025-12-21 18:19:37 - Улправда
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Down 3.6% – Time to Sell? - Defense World
Noble Financial Sticks to Their Buy Rating for Greenwich LifeSciences (GLSI) - The Globe and Mail
Will Gyre Therapeutics Inc. stock keep outperforming rivalsJuly 2025 Breakouts & Low Drawdown Investment Strategies - Улправда
Gyre Therapeutics Earnings Notes - Trefis
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Down 3.6%Time to Sell? - MarketBeat
Why Gyre Therapeutics Inc. stock remains on buy lists2025 Trading Recap & Long-Term Capital Growth Strategies - Улправда
Levels Update: Is Gyre Therapeutics Inc. stock vulnerable to regulatory risks2025 Major Catalysts & Weekly Momentum Picks - Улправда
Gyre Therapeutics Inc Azioni (GYRE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Gyre Therapeutics Inc Azioni (GYRE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Ma Songjiang | President |
May 27 '25 |
Sale |
10.28 |
2,000 |
20,560 |
2,806,642 |
| Ma Songjiang | President |
May 28 '25 |
Sale |
10.07 |
558 |
5,619 |
2,806,084 |
| Ma Songjiang | President |
May 22 '25 |
Sale |
10.97 |
2,000 |
21,940 |
2,808,824 |
| Ma Songjiang | President |
May 23 '25 |
Sale |
10.24 |
182 |
1,864 |
2,808,642 |
| Ma Songjiang | President |
May 20 '25 |
Sale |
11.25 |
2,000 |
22,500 |
2,812,824 |
| Ma Songjiang | President |
May 21 '25 |
Sale |
10.83 |
2,000 |
21,660 |
2,810,824 |
| Ma Songjiang | President |
May 16 '25 |
Sale |
11.31 |
2,000 |
22,620 |
2,816,824 |
| Ma Songjiang | President |
May 19 '25 |
Sale |
11.11 |
2,000 |
22,220 |
2,814,824 |
| Ma Songjiang | President |
May 15 '25 |
Sale |
10.68 |
2,000 |
21,360 |
2,818,824 |
| Ma Songjiang | President |
May 14 '25 |
Sale |
11.30 |
20 |
226 |
2,820,824 |
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):